Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

DiPersio, J., Cooper, B. W., Suh, H. C., Koura, D., Bernard, L., Shah, N. N., Walter, R. B., Perales, M.-A., Mapara, M., Tamari, R., Loken, M. R., Breitschwerdt, K., Nath, S., Raffel, G. D., & Koehne, G. (2023). Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT). Blood, 142(Supplement 1), 483–483. https://doi.org/10.1182/blood-2023-190037
Authors:
John F. DiPersio
Matthew Cooper
Hyung Chan Suh
Divya Koura
Léa Bernard
Nirali N. Shah
Roland B. Walter
Miguel‐Angel Perales
Markus Y. Mapara
Roni Tamari
Michael R. Loken
Kyle Breitschwerdt
Sritama Nath
Glen Raffel
Guenther Koehne
Affiliated Authors:
Markus Y. Mapara
Columbia Affiliation:
Subjects:
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Acute Myeloid Leukemia (OpenAlex Topic)
Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-190037
DOI:
10.1182/blood-2023-190037
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: